In addition, patients in the Phase 2 rucaparib study who had BRCA1/2 wild-type status had mutations in non-BRCA homologous recombination genes, including ATM, RAD51C and RAD51D, which led to approval of rucaparib for the maintenance treatment of patients with ovarian cancer regardless of BRCA1/2 status [23, 24]. The gene discussed is ATM; the disease is ovarian carcinoma.